Medincell’s Post

🎥 Exclusive Video Premiere! 🌟 New Milestones & Inspiring Video from Cytonics Corporation - Witness Our Evolution In Realtime! Become a shareholder: invest.cytonics.com 🎬 A Video Says 10,000 Words With immense pride and excitement, we're thrilled to bring you an update that marks not just progress but a leap towards a future where osteoarthritis can be effectively managed and treated. Today, we unveil a series of pivotal milestones accompanied by a brand-new marketing video that encapsulates the essence of our mission, the depth of our commitment, and the potential of our groundbreaking work. 🎉 2024 Is Off With A Bang! We are only 3 months in, and before quarter end we will have accomplished these major milestones on our path towards human clinical trials: 📜 Regulatory Submission Completed: We've successfully navigated the complex regulatory landscape to submit the necessary documents, setting the stage for our next phase of trials. 🧪 Phase 1 Protocol Finalized: Our meticulous planning has culminated in the finalization of the Phase 1 study protocol for CYT-108, ensuring a focused and effective evaluation process. 🏥 Clinical Site Activation: With strategic site selections, we're now poised to commence patient recruitment, bringing us closer to the real-world impact of our research. 🧬 GMP Manufacturing and Delivery: Achieving a significant benchmark, the Good Manufacturing Practice (GMP) manufacturing of CYT-108 has been completed, and our preparations are now in place at the clinical trial sites . 🤝 Collaboration with Australian CRO: Partnering with Southern Star Research, a leading Contract Research Organization in Australia, we're ensuring that the Phase 1 study of CYT-108 is managed with the utmost precision and expertise. ❤️ We Cherish Our Investors!  Your unwavering support has been crucial to our journey thus far. As we embark on this new chapter, filled with promise and potential, we invite you to continue standing with us. As an investor, you are joining a family of passionate scientists and physicians, Hell bent on saving the lives of over 600M people worldwide. Stay tuned for more updates as we forge ahead with our mission to revolutionize the treatment of osteoarthritis. Together, we are not just witnessing history. We are making it. #biotechnology #drugdevelopment #arthritis #clinicaltrials #pharmaceutical #investing #crowdfunding

🎥 Exclusive Video Premiere! 🌟 New Milestones & Inspiring Video from Cytonics Corporation - Witness Our Evolution! Become a shareholder: invest.cytonics.com 🎬 A Video Says 10,000 Words With immense pride and excitement, we're thrilled to bring you an update that marks not just progress but a leap towards a future where osteoarthritis can be effectively managed and treated. Today, we unveil a series of pivotal milestones accompanied by a brand-new marketing video that encapsulates the essence of our mission, the depth of our commitment, and the potential of our groundbreaking work. 🎉 2024 Is Off With A Bang! We are only 3 months in, and before quarter end we will have accomplished these major milestones on our path towards human clinical trials: 📜 Regulatory Submission Completed: We've successfully navigated the complex regulatory landscape to submit the necessary documents, setting the stage for our next phase of trials. 🧪 Phase 1 Protocol Finalized: Our meticulous planning has culminated in the finalization of the Phase 1 study protocol for CYT-108, ensuring a focused and effective evaluation process. 🏥 Clinical Site Activation: With strategic site selections, we're now poised to commence patient recruitment, bringing us closer to the real-world impact of our research. 🧬 GMP Manufacturing and Delivery: Achieving a significant benchmark, the Good Manufacturing Practice (GMP) manufacturing of CYT-108 has been completed, and our preparations are now in place at the clinical trial sites . 🤝 Collaboration with Australian CRO: Partnering with Southern Star Research, a leading Contract Research Organization in Australia, we're ensuring that the Phase 1 study of CYT-108 is managed with the utmost precision and expertise. ❤️ We Cherish Our Investors!  Your unwavering support has been crucial to our journey thus far. As we embark on this new chapter, filled with promise and potential, we invite you to continue standing with us. As an investor, you are joining a family of passionate scientists and physicians, Hell bent on saving the lives of over 600M people worldwide. Stay tuned for more updates as we forge ahead with our mission to revolutionize the treatment of osteoarthritis. Together, we are not just witnessing history. We are making it. #biotechnology #drugdevelopment #arthritis #clinicaltrials #pharmaceutical #investing #crowdfunding

🎥 Exclusive Video Premiere! 🌟 New Milestones & Inspiring Video from Cytonics Corporation - Witness Our Evolution! Become a shareholder: invest.cytonics.com 🎬 A Video Says 10,000 Words With immense pride and excitement, we're thrilled to bring you an update that marks not just progress but a leap towards a future where osteoarthritis can be effectively managed and treated. Today, we unveil a series of pivotal milestones accompanied by a brand-new marketing video that encapsulates the essence of our mission, the depth of our commitment, and the potential of our groundbreaking work. 🎉 2024 Is Off With A Bang! We are only 3 months in, and before quarter end we will have accomplished these major milestones on our path towards human clinical trials: 📜 Regulatory Submission Completed: We've successfully navigated the complex regulatory landscape to submit the necessary documents, setting the stage for our next phase of trials. 🧪 Phase 1 Protocol Finalized: Our meticulous planning has culminated in the finalization of the Phase 1 study protocol for CYT-108, ensuring a focused and effective evaluation process. 🏥 Clinical Site Activation: With strategic site selections, we're now poised to commence patient recruitment, bringing us closer to the real-world impact of our research. 🧬 GMP Manufacturing and Delivery: Achieving a significant benchmark, the Good Manufacturing Practice (GMP) manufacturing of CYT-108 has been completed, and our preparations are now in place at the clinical trial sites . 🤝 Collaboration with Australian CRO: Partnering with Southern Star Research, a leading Contract Research Organization in Australia, we're ensuring that the Phase 1 study of CYT-108 is managed with the utmost precision and expertise. ❤️ We Cherish Our Investors!  Your unwavering support has been crucial to our journey thus far. As we embark on this new chapter, filled with promise and potential, we invite you to continue standing with us. As an investor, you are joining a family of passionate scientists and physicians, Hell bent on saving the lives of over 600M people worldwide. Stay tuned for more updates as we forge ahead with our mission to revolutionize the treatment of osteoarthritis. Together, we are not just witnessing history. We are making it. #biotechnology #drugdevelopment #arthritis #clinicaltrials #pharmaceutical #investing #crowdfunding

MARKET ACCESS RESEARCH: Prescription digital therapeutics will see increased activity by 2025, with 47 percent of #payers, #IDNs, and other stakeholders planning to execute #PDT strategies by then, according to our Second Annual Market Access Survey. “Organizations desire additional clarity regarding the value of prescription therapeutics and reimbursement,” said Valuate Principal Tony Gibson, who supervised the survey. “CMS and FDA activity in this area will also spur payer planning in this area.” In addition to the PDT activity, 40 percent of respondents say they will execute #AI plans by 2025 for administrative and manual functions, including streamlining #priorauthorization. The next AI frontier may focus on patient engagement and patient decision-making tools, respondents say. #marketaccess #pharma #biotech

Pharma's #digitalhealth investments are being clawed back and innovation hubs restructured. Approaches to #HealthTech are shifting and #MedTech could be the new path forward. Register here https://lnkd.in/eQnbTPWb to join pharma and MedTech experts from Roche, Novo Nordisk, Merck Group, Novartis and ViiV Healthcare as we carve out pharma's future in the MedTech space.

Big news from Gilead Sciences! The company has made a strategic decision to write off $2.4 billion related to its recent acquisition of Trodelvy. This move underscores Gilead's commitment to maintaining a focused and agile approach in its pursuit of innovative solutions to address unmet medical needs. While the decision to write off a significant portion of the investment may seem surprising at first glance, it reflects Gilead's disciplined approach to portfolio management. By carefully evaluating the potential of each asset within its pipeline, Gilead can reallocate resources to areas where they can have the greatest impact on patient outcomes. As Gilead's CEO emphasizes, this decision does not detract from the company's dedication to advancing transformative therapies that have the potential to make a meaningful difference in patients' lives. Rather, it underscores the importance of prioritizing investments that align closely with Gilead's strategic objectives and therapeutic focus areas. Innovation remains at the heart of Gilead's mission, and the company remains steadfast in its commitment to bringing forward novel treatments that address significant medical challenges. By maintaining a sharp focus on areas of expertise and therapeutic excellence, Gilead continues to drive progress in the field of biopharmaceuticals and improve health outcomes for patients around the world. #GileadSciences #Trodelvy #Biopharma #Innovation #Healthcare #Biotech #Investment #PortfolioManagement #TherapeuticFocus #Pharmacist

Join our Chief Medical Officer, Dr Mert Aral, at DTx East today to discover how digital therapeutics, pharmaceuticals, and technology are reshaping the healthcare landscape. In his presentation, Mert will explore: 🌐 How the emergence of AI and technology is catalysing healthcare transformation 🔐 Why regulation is a linchpin for propelling health innovation forward 💡 Impactful use cases of DTx benefiting both pharma and patients 📚 Valuable lessons drawn from successful real-world partnerships. 🗓️ Date: Tuesday, September 26 🕒 Time: 12:05 PM See you there! 🚀 https://lnkd.in/evG_gfUz #HumaforHealth #DTxEast #HealthcareTransformation #DTxPartnerships #DigitalTherapeutics #PharmaInnovation #DTxEast2023

New deal struck between Viatris and Idorsia Pharmaceuticals Ltd A global R&D collaboration; "Viatris will gain exclusive global development and commercialization rights to two Phase 3 assets: selatogrel, a self-administered medicine for patients with a history of acute myocardial infarction (AMI), and cenerimod, a novel oral therapy being developed for the treatment of systemic lupus erythematosus (SLE)." Selatogrel aims to protect heart muscle during the early phase of AMI, while cenerimod holds potential for multiple autoimmune diseases and could be a cornerstone asset in Viatris’ immunology platform. https://lnkd.in/eWyy3QFF #Viatris #Idorsia #Collaboration #Innovation #Pharma #Healthcare